busulfan has been researched along with Body Weight in 58 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose of a widely studied agent in this setting, busulfan, can be adjusted based on area under the curve (AUC); however, choice of actual body weight (ABW) versus adjusted body weight (DBW) weight to calculate the initial dose may be critical in attaining goal AUC." | 7.81 | Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? ( Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S, 2015) |
| "The model-based individual dosing nomogram is expected to result in predictive busulfan exposures in patients ranging between 3 and 65 kg and thereby to a safer and more effective conditioning regimen for HSCT in children." | 6.48 | Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. ( Bartelink, IH; Bierings, MB; Boelens, JJ; Bredius, RG; Danhof, M; Egberts, AC; Hempel, G; Knibbe, CA; Nath, CE; Shaw, PJ; Wang, C; Zwaveling, J, 2012) |
| "Weight-based dosing of intravenous busulfan is widely used in hematopoietic cell transplantation." | 5.51 | Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. ( Griffin, SP; Hsu, JW; Murthy, HS; Richards, AI; Wheeler, SE; Wiggins, LE, 2019) |
| " The dosing nomogram for every 6 h administration derived from the final model is: dose[mg]=target AUC[mg×h/L]×3." | 5.40 | Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing. ( Boos, J; Diestelhorst, C; Hempel, G; McCune, JS, 2014) |
| "To evaluate the best method for dosing busulfan in children, we retrospectively analyzed two different data sets from three different dosing regimens by means of population pharmacokinetics using NONMEM." | 5.37 | Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. ( Bergstrand, M; Boos, J; Hempel, G; Karlsson, MO; Trame, MN, 2011) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 5.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| "A new intravenous (IV) dosing of busulfan (Bu) based on body weight, designed to improve AUC targeting without TDM and dose-adjustment, was prospectively evaluated." | 5.13 | Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. ( Doz, F; Espérou, H; Galambrun, C; Gentet, JC; Mechinaud, F; Michel, G; Neven, B; Nguyen, L; Puozzo, C; Valteau-Couanet, D; Vassal, G; Zouabi, H, 2008) |
| "Intravenous (IV) busulfan (Bu) dosing approved in Europe based on 5 body weight (BW) strata has been validated for targeting Bu exposures in children undergoing hematopoietic stem-cell transplantation and with mostly malignant diseases." | 4.88 | Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. ( Abdi, ZD; Bleyzac, N; Broutin, S; Dalle, JH; Galambrun, C; Kemmel, V; Moshous, D; Neven, B; Nguyen, L; Paci, A; Pétain, A; Vassal, G, 2012) |
| "Treosulfan disposition was described through allometric body weight and maturational age descriptors." | 4.31 | Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations. ( Chung, J; Fraser, C; Keogh, SJ; Kohli, S; Lee, S; McLachlan, AJ; Nath, CE; O'Brien, T; Rosser, SPA; Shaw, PJ, 2023) |
| " The dose of a widely studied agent in this setting, busulfan, can be adjusted based on area under the curve (AUC); however, choice of actual body weight (ABW) versus adjusted body weight (DBW) weight to calculate the initial dose may be critical in attaining goal AUC." | 3.81 | Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? ( Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S, 2015) |
| "Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation." | 3.80 | The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children. ( Branova, R; Janeckova, D; Keslova, P; Klapkova, E; Malis, J; Prusa, R; Riha, P; Sedlacek, P; Tesfaye, H, 2014) |
| " For an optimal area under the curve (AUC) targeting, a new Bu dosing regimen [i." | 2.73 | Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience. ( Nguyen, L, 2008) |
| "The objective of this study was to characterize the pharmacokinetics (PK) of intravenous busulfan in pediatric patients and provide dosing recommendations." | 2.73 | Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. ( Booth, BP; Dagher, R; Fuller, D; Gobburu, JV; Griebel, D; Lennon, S; Mehta, M; Rahman, A; Sahajwalla, C, 2007) |
| " Patient weight, age, glutathione-S-transferase A1 (GSTA1) genotype and busulfan dosing day/time were the most commonly identified factors affecting CL." | 2.72 | Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. ( Fraser, CJ; Hennig, S; Lawson, R; Staatz, CE, 2021) |
| " Initial dosing of i." | 2.71 | I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. ( Fuller, D; Leger, F; Lennon, S; Nguyen, L; Puozzo, C, 2004) |
| "Fifty-two BMT institutions were sent a questionnaire asking for details of dosing for busulphan, cyclophosphamide (bu-cy), cyclosporin and methotrexate (CSA-MTX)." | 2.68 | Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. ( Grigg, A; Harun, MH; Szer, J, 1997) |
| "Allometric approaches are widely used for interspecies scaling for the prediction of pharmacokinetic (PK) parameters during drug development." | 2.58 | Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants. ( Forshee, R; Jiang, Z; Mahmood, I; Tegenge, MA, 2018) |
| " We then compared the probability of cAUC within the range of 80 to 100 mg · h/L by the developed dosing regimen versus conventional regimen." | 1.72 | Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis. ( Gupta, AO; Illamola, SM; Jennissen, CA; Long, SE; Long-Boyle, JR; Lund, TC; Orchard, PJ; Takahashi, T, 2022) |
| "This study aimed to characterize the population pharmacokinetics (PK) of busulfan focusing on how busulfan clearance (CL) changes over time during once-daily administration and assess different methods for measuring busulfan exposure and the ability to achieve target cumulative exposure under different dosing adjustment scenarios in pediatric stem cell transplantation recipients." | 1.72 | Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance. ( Fraser, CJ; Hennig, S; Lawson, R; Mitchell, R; O'Brien, T; Ramachandran, S; Staatz, CE; Teague, L, 2022) |
| "Busulfan is a bifunctional alkylating agent used for myeloablative conditioning and in the treatment of chronic myeloid leukemia due to its ability to cause DNA damage." | 1.56 | Maternal exposure to busulfan reduces the cell number in the somatosensory cortex associated with delayed somatic and reflex maturation in neonatal rats. ( Albuquerque, G; Costa-de-Santana, BJR; Gouveia, HJCB; Lacerda, DC; Manhães-de-Castro, R; Mendonça, CR; Toscano, AE; Visco, DB, 2020) |
| "Weight-based dosing of intravenous busulfan is widely used in hematopoietic cell transplantation." | 1.51 | Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients. ( Griffin, SP; Hsu, JW; Murthy, HS; Richards, AI; Wheeler, SE; Wiggins, LE, 2019) |
| " A model-based dosing table is presented to target an exposure of 1650 mg*h/L (population median) for different weight and age groups." | 1.51 | Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. ( Bertaina, A; Guchelaar, HJ; Lankester, AC; Locatelli, F; Moes, DJAR; van der Stoep, MYEC; Zwaveling, J, 2019) |
| " We aimed this retrospective study for comparison of weight- and age-based dosing in terms of clinical outcomes such as time to engraftment, early complications, EFS, OS, and toxicity profiles in children receiving iv Bu." | 1.42 | Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. ( Avci, Z; Azik, F; Gürlek Gökçebay, D; Isik, P; Kara, A; Ozbek, N; Tavil, B; Tunc, B, 2015) |
| " The relationship between CL and body weight was used to revise the initial IV dosing schedule." | 1.40 | Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? ( Allen, KM; Barclay, ML; Begg, EJ; Buffery, PJ; Chin, PK; Moore, GA, 2014) |
| "Oral mucositis is one of the most debilitating side effects in patient undergoing chemotherapy or chemoradiotherapy." | 1.40 | Protective effects of aqueous extract of Solanum nigrum Linn. leaves in rat models of oral mucositis. ( Biswas, S; Nandakumar, K; Patel, A; Ramalingayya, GV; Shoja, MH, 2014) |
| "The new dosing schedule using IV Bu provides adequate therapeutic targeting from the first administration, with low toxicity and good disease control in high-risk children." | 1.38 | Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. ( Bertrand, Y; Bordigoni, P; Demeocq, F; Doz, F; Esperou, H; Frappaz, D; Galambrun, C; Gentet, JC; Méchinaud, F; Michel, G; Neven, B; Nguyen, L; Socié, G; Valteau-Couanet, D; Vassal, G; Yakouben, K, 2012) |
| "Recently a pediatric pharmacokinetic (PK) model was developed for busulfan to explain the wide variability in PK of busulfan in children, as this variability is known to influence the outcome of hematopoietic stem cell transplantation in terms of toxicity and event free survival." | 1.38 | Predictive performance of a busulfan pharmacokinetic model in children and young adults. ( Bartelink, IH; Bierings, MB; Boelens, JJ; Chiesa, R; Cuvelier, GD; Danhof, M; Egberts, TC; Knibbe, CA; Slatter, MA; van Kesteren, C; Wynn, RF, 2012) |
| "To evaluate the best method for dosing busulfan in children, we retrospectively analyzed two different data sets from three different dosing regimens by means of population pharmacokinetics using NONMEM." | 1.37 | Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. ( Bergstrand, M; Boos, J; Hempel, G; Karlsson, MO; Trame, MN, 2011) |
| "The effect of glutathione S-transferase variants on pediatric busulfan metabolism was investigated by noncompartmental and population pharmacokinetic modeling." | 1.35 | Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. ( Baker, KS; Brundage, R; Cao, Q; Farag-El Maasah, S; Jacobson, PA; Johnson, L; Langer, E; Orchard, PJ; Remmel, R; Ross, JA; Wang, X, 2008) |
| " Recent data revealed immunosuppressive characteristics and substantial haematopoietic stem cell toxicity after repeated dosing of mice." | 1.32 | Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). ( Baumgart, J; Becker, M; Fichtner, I, 2003) |
| "The aims of the present study were (1) to investigate and quantify the pharmacokinetics, including inter-occasion variability and covariate relationships, of busulphan in BMT patients and (2) to develop a user-friendly initial dosing and therapeutic drug monitoring (TDM) strategy for the treatment of those patients with busulphan." | 1.31 | Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. ( Bekassy, A; Hassan, M; Hassan, Z; Jonsson, EN; Karlsson, MO; Ljungman, P; Nilsson, C; Oberg, G; Ringden, O; Sandström, M, 2001) |
| " Routine dosing on the basis of BSA or AIBW in adults and adolescents does not require a specific accommodation for the obese." | 1.30 | The impact of obesity and disease on busulfan oral clearance in adults. ( Appelbaum, FR; Corneau, B; Gibbs, JP; Gooley, T; Murray, G; Slattery, JT; Stewart, P, 1999) |
| "Flutamide treatment decreased the weight of accessory sex organs, stimulated the secretion of both LH (+200%) and FSH (+63%) by inhibition of the negative feedback of testosterone; endogenous testosterone secretion was increased by 363%." | 1.27 | Effects of flutamide or of supplementation with testosterone in prepubertal male rats prenatally treated with busulfan. ( Hochereau-de Reviers, MT; Perreau, C; Viguier-Martinez, MC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (20.69) | 18.7374 |
| 1990's | 5 (8.62) | 18.2507 |
| 2000's | 12 (20.69) | 29.6817 |
| 2010's | 19 (32.76) | 24.3611 |
| 2020's | 10 (17.24) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, T | 1 |
| Illamola, SM | 1 |
| Jennissen, CA | 1 |
| Long, SE | 1 |
| Lund, TC | 1 |
| Orchard, PJ | 2 |
| Gupta, AO | 1 |
| Long-Boyle, JR | 1 |
| Lawson, R | 2 |
| Staatz, CE | 2 |
| Fraser, CJ | 2 |
| Ramachandran, S | 1 |
| Teague, L | 1 |
| Mitchell, R | 1 |
| O'Brien, T | 2 |
| Hennig, S | 2 |
| Rosser, SPA | 1 |
| Lee, S | 1 |
| Kohli, S | 1 |
| Keogh, SJ | 1 |
| Chung, J | 1 |
| Fraser, C | 1 |
| McLachlan, AJ | 1 |
| Shaw, PJ | 2 |
| Nath, CE | 2 |
| Yang, ZZ | 1 |
| Wang, XL | 1 |
| Zhang, D | 1 |
| Ma, S | 1 |
| Zheng, LW | 1 |
| Teitelbaum, Z | 1 |
| Nassar, L | 1 |
| Scherb, I | 1 |
| Fink, D | 1 |
| Ring, G | 1 |
| Lurie, Y | 1 |
| Krivoy, N | 1 |
| Bentur, Y | 1 |
| Efrati, E | 1 |
| Kurnik, D | 1 |
| Gouveia, HJCB | 1 |
| Manhães-de-Castro, R | 1 |
| Costa-de-Santana, BJR | 1 |
| Mendonça, CR | 1 |
| Albuquerque, G | 1 |
| Visco, DB | 1 |
| Lacerda, DC | 1 |
| Toscano, AE | 1 |
| Qu, N | 1 |
| Kuramasu, M | 1 |
| Nagahori, K | 1 |
| Ogawa, Y | 1 |
| Hayashi, S | 1 |
| Hirayanagi, Y | 1 |
| Terayama, H | 1 |
| Suyama, K | 1 |
| Sakabe, K | 1 |
| Itoh, M | 1 |
| Abarikwu, SO | 1 |
| Mgbudom-Okah, CJ | 1 |
| Onuah, CL | 1 |
| Neroutsos, E | 1 |
| Athanasiadou, I | 1 |
| Paisiou, A | 1 |
| Zisaki, K | 1 |
| Goussetis, E | 1 |
| Archontaki, H | 1 |
| Tsirigotis, P | 1 |
| Kitra, M | 1 |
| Grafakos, S | 1 |
| Spyridonidis, A | 1 |
| Dokoumetzidis, A | 1 |
| Valsami, G | 1 |
| Tegenge, MA | 1 |
| Mahmood, I | 1 |
| Jiang, Z | 1 |
| Forshee, R | 1 |
| Griffin, SP | 1 |
| Wheeler, SE | 1 |
| Wiggins, LE | 1 |
| Murthy, HS | 1 |
| Hsu, JW | 1 |
| Richards, AI | 1 |
| van der Stoep, MYEC | 1 |
| Zwaveling, J | 2 |
| Bertaina, A | 1 |
| Locatelli, F | 1 |
| Guchelaar, HJ | 1 |
| Lankester, AC | 1 |
| Moes, DJAR | 1 |
| Jiang, Y | 1 |
| Zhang, Z | 1 |
| Cha, L | 1 |
| Li, L | 1 |
| Zhu, D | 1 |
| Fang, Z | 1 |
| He, Z | 1 |
| Huang, J | 1 |
| Pan, Z | 1 |
| Chevaleyre, J | 1 |
| Duchez, P | 1 |
| Rodriguez, L | 1 |
| Vlaski, M | 1 |
| Villacreces, A | 1 |
| Conrad-Lapostolle, V | 1 |
| Praloran, V | 1 |
| Ivanovic, Z | 1 |
| Brunet de la Grange, P | 1 |
| Buffery, PJ | 1 |
| Allen, KM | 1 |
| Chin, PK | 1 |
| Moore, GA | 1 |
| Barclay, ML | 1 |
| Begg, EJ | 1 |
| de Berranger, E | 1 |
| Cousien, A | 1 |
| Petit, A | 1 |
| Peffault de Latour, R | 1 |
| Galambrun, C | 4 |
| Bertrand, Y | 2 |
| Salmon, A | 1 |
| Rialland, F | 1 |
| Rohrlich, PS | 1 |
| Vannier, JP | 2 |
| Lutz, P | 2 |
| Yakouben, K | 2 |
| Duhamel, A | 1 |
| Bruno, B | 1 |
| Michel, G | 3 |
| Dalle, JH | 2 |
| Diestelhorst, C | 1 |
| Boos, J | 2 |
| McCune, JS | 1 |
| Hempel, G | 3 |
| Tesfaye, H | 1 |
| Branova, R | 1 |
| Klapkova, E | 1 |
| Prusa, R | 1 |
| Janeckova, D | 1 |
| Riha, P | 1 |
| Sedlacek, P | 1 |
| Keslova, P | 1 |
| Malis, J | 1 |
| Clemmons, AB | 1 |
| Evans, S | 1 |
| DeRemer, DL | 1 |
| Awan, FT | 1 |
| Patel, A | 1 |
| Biswas, S | 1 |
| Shoja, MH | 1 |
| Ramalingayya, GV | 1 |
| Nandakumar, K | 1 |
| Gürlek Gökçebay, D | 1 |
| Azik, F | 1 |
| Ozbek, N | 1 |
| Isik, P | 1 |
| Avci, Z | 1 |
| Tavil, B | 1 |
| Kara, A | 1 |
| Tunc, B | 1 |
| Lai, D | 1 |
| Wang, F | 1 |
| Yao, X | 1 |
| Zhang, Q | 1 |
| Wu, X | 1 |
| Xiang, C | 1 |
| Johnson, L | 1 |
| Baker, KS | 1 |
| Brundage, R | 1 |
| Cao, Q | 1 |
| Wang, X | 1 |
| Langer, E | 1 |
| Farag-El Maasah, S | 1 |
| Ross, JA | 1 |
| Remmel, R | 1 |
| Jacobson, PA | 1 |
| Nguyen, L | 5 |
| Valteau-Couanet, D | 3 |
| Gentet, JC | 2 |
| Esperou, H | 2 |
| Socié, G | 1 |
| Méchinaud, F | 3 |
| Doz, F | 2 |
| Neven, B | 3 |
| Demeocq, F | 1 |
| Bordigoni, P | 1 |
| Frappaz, D | 1 |
| Vassal, G | 4 |
| Trame, MN | 1 |
| Bergstrand, M | 1 |
| Karlsson, MO | 2 |
| Al-Hashmi, S | 1 |
| Boels, PJ | 1 |
| Zadjali, F | 1 |
| Sadeghi, B | 2 |
| Sällström, J | 1 |
| Hultenby, K | 1 |
| Hassan, Z | 4 |
| Arner, A | 1 |
| Hassan, M | 4 |
| Paci, A | 1 |
| Moshous, D | 1 |
| Bleyzac, N | 1 |
| Kemmel, V | 1 |
| Abdi, ZD | 1 |
| Broutin, S | 1 |
| Pétain, A | 1 |
| Bartelink, IH | 2 |
| Boelens, JJ | 2 |
| Bredius, RG | 1 |
| Egberts, AC | 1 |
| Wang, C | 1 |
| Bierings, MB | 2 |
| Danhof, M | 2 |
| Knibbe, CA | 2 |
| van Kesteren, C | 1 |
| Egberts, TC | 1 |
| Cuvelier, GD | 1 |
| Wynn, RF | 1 |
| Slatter, MA | 1 |
| Chiesa, R | 1 |
| Lee, JH | 2 |
| Lee, KH | 1 |
| Kim, S | 1 |
| Seol, M | 1 |
| Park, CJ | 1 |
| Chi, HS | 1 |
| Kang, W | 1 |
| Kim, ST | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Fichtner, I | 1 |
| Becker, M | 1 |
| Baumgart, J | 1 |
| Fuller, D | 2 |
| Lennon, S | 2 |
| Leger, F | 1 |
| Puozzo, C | 2 |
| Booth, BP | 1 |
| Rahman, A | 1 |
| Dagher, R | 1 |
| Griebel, D | 1 |
| Sahajwalla, C | 1 |
| Mehta, M | 1 |
| Gobburu, JV | 1 |
| Zouabi, H | 1 |
| Jansson, M | 1 |
| Mints, M | 1 |
| Hägglund, H | 1 |
| Abedi-Valugerdi, M | 1 |
| Molyneux, G | 1 |
| Gibson, FM | 1 |
| Whayman, M | 1 |
| Turton, JA | 1 |
| Láznicka, M | 1 |
| Slattery, JT | 2 |
| Sanders, JE | 1 |
| Buckner, CD | 1 |
| Schaffer, RL | 1 |
| Lambert, KW | 1 |
| Langer, FP | 1 |
| Anasetti, C | 1 |
| Bensinger, WI | 1 |
| Fisher, LD | 1 |
| Appelbaum, FR | 2 |
| Kanold, J | 1 |
| Berger, M | 1 |
| Rapatel, C | 1 |
| de Lumley, L | 1 |
| Plantaz, D | 1 |
| Bergeron, C | 1 |
| Favrot, M | 1 |
| Grigg, A | 1 |
| Harun, MH | 1 |
| Szer, J | 1 |
| Jiang, FX | 1 |
| Gibbs, JP | 1 |
| Gooley, T | 1 |
| Corneau, B | 1 |
| Murray, G | 1 |
| Stewart, P | 1 |
| Benhamou, E | 1 |
| Stambouli, F | 1 |
| Lapierre, V | 1 |
| Couanet, D | 1 |
| Lumbroso, J | 1 |
| Hartmann, O | 1 |
| Ljungman, P | 2 |
| Ringdén, O | 2 |
| Winiarski, J | 1 |
| Nilsson, C | 2 |
| Aschan, J | 1 |
| Whitley, HR | 1 |
| Sandström, M | 1 |
| Jonsson, EN | 1 |
| Oberg, G | 1 |
| Bekassy, A | 1 |
| Tutschka, PJ | 1 |
| Santos, GW | 1 |
| Laporte, P | 1 |
| Gillet, J | 1 |
| Kasuga, F | 1 |
| Takahashi, M | 1 |
| Kantarjian, HM | 1 |
| Smith, TL | 1 |
| McCredie, KB | 1 |
| Keating, MJ | 1 |
| Walters, RS | 1 |
| Talpaz, M | 1 |
| Hester, JP | 1 |
| Bligham, G | 1 |
| Gehan, E | 1 |
| Freireich, EJ | 1 |
| Viguier-Martinez, MC | 1 |
| Hochereau-de Reviers, MT | 1 |
| Perreau, C | 1 |
| Jansz, GF | 1 |
| Pomerantz, DK | 1 |
| Claus-Walker, J | 1 |
| Thompson, EN | 1 |
| Soothill, JF | 1 |
| Leonard, A | 1 |
| Linden, G | 1 |
| Debeljuk, L | 1 |
| Arimura, A | 1 |
| Schally, AV | 1 |
| Hall, RW | 1 |
| Gomes, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation[NCT02670252] | Phase 3 | 550 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for busulfan and Body Weight
| Article | Year |
|---|---|
Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.
Topics: Administration, Intravenous; Body Weight; Busulfan; Child; Genotype; Hematopoietic Stem Cell Transpl | 2021 |
Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants.
Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Alfentanil; Body Weight; Busulfan; Chil | 2018 |
Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Topics: Adolescent; Age Factors; Area Under Curve; Body Weight; Busulfan; Child; Child, Preschool; Cohort St | 2012 |
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Topics: Adolescent; Adult; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Dose-Response Relati | 2012 |
6 trials available for busulfan and Body Weight
| Article | Year |
|---|---|
Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.
Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Computer Simulation; Drug A | 2008 |
I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; | 2004 |
Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
Topics: Age Factors; Alkylating Agents; Body Surface Area; Body Weight; Busulfan; Child; Child, Preschool; C | 2007 |
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; | 2008 |
Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey.
Topics: Adult; Body Weight; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Dose-Resp | 1997 |
Pharmacokinetics of liposomal busulphan in man.
Topics: Adolescent; Adult; Area Under Curve; Body Weight; Busulfan; Child; Female; Hematopoietic Stem Cell T | 2001 |
48 other studies available for busulfan and Body Weight
| Article | Year |
|---|---|
Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
Topics: Body Weight; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Metabolic Diseases; T | 2022 |
Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.
Topics: Administration, Intravenous; Adult; Body Weight; Busulfan; Child; Humans; Kinetics; Male | 2022 |
Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
Topics: Adolescent; Body Weight; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; | 2023 |
[Therapeutic effect of Heirong Kidney-Tonifying Granule on busulfan-induced dyszoospermia in model mice].
Topics: Animals; Body Weight; Busulfan; Kidney; Male; Mice; Semen; Sertoli Cells; Spermatogenesis; Testis | 2022 |
Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults.
Topics: Adolescent; Age Factors; Area Under Curve; Body Surface Area; Body Weight; Busulfan; Child; Child, P | 2020 |
Maternal exposure to busulfan reduces the cell number in the somatosensory cortex associated with delayed somatic and reflex maturation in neonatal rats.
Topics: Alkylating Agents; Animals; Behavior, Animal; Body Weight; Busulfan; Cell Count; Female; Maternal Ex | 2020 |
Co-Administration of the Traditional Medicines Hachimi-Jio-Gan and Hochu-Ekki-To Can Reverse Busulfan-Induced Aspermatogenesis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Body Weight; Busulfan; Cell Proliferation; Di | 2020 |
The protective effect of rutin against busulfan-induced testicular damage in adult rats.
Topics: Animals; Antioxidants; Body Weight; Busulfan; Male; Oxidative Stress; Rats; Rats, Wistar; Rutin; Tes | 2022 |
Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Area Under Curve; Body Weight; Bone Mar | 2021 |
Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Body Weight; Busulfan; Disease-Free Survival; Drug Dosage Calculations; Hem | 2019 |
Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Biological Variation, Population; Body W | 2019 |
Resveratrol Plays a Protective Role against Premature Ovarian Failure and Prompts Female Germline Stem Cell Survival.
Topics: Animals; Antioxidants; Body Weight; Busulfan; Catalase; Cell Survival; Coculture Techniques; DEAD-bo | 2019 |
Busulfan administration flexibility increases the applicability of scid repopulating cell assay in NSG mouse model.
Topics: Animals; Body Weight; Busulfan; Cell Differentiation; Female; Graft Survival; Hematopoietic Stem Cel | 2013 |
Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Blood Specimen Collection; B | 2014 |
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Topics: Adolescent; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; France; Graft | 2014 |
Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.
Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Body Surface Area; Bod | 2014 |
The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
Topics: Adjuvants, Immunologic; Adolescent; Body Weight; Busulfan; Child; Child, Preschool; Chromatography, | 2014 |
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Body | 2015 |
Protective effects of aqueous extract of Solanum nigrum Linn. leaves in rat models of oral mucositis.
Topics: Animals; Body Weight; Busulfan; Chromatography, High Pressure Liquid; Disease Models, Animal; Feedin | 2014 |
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.
Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; F | 2015 |
Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure.
Topics: Adult; Animals; Body Weight; Busulfan; Cell Differentiation; Cyclophosphamide; Disease Models, Anima | 2015 |
Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.
Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Computer Simulation; Female | 2008 |
Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Child; Child | 2012 |
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Body Surface Area; Body Weight; Bone Marrow Transplan | 2011 |
Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.
Topics: Acetylcholine; Animals; Aorta; Biomechanical Phenomena; Blood Pressure; Body Weight; Busulfan; Colfo | 2012 |
Predictive performance of a busulfan pharmacokinetic model in children and young adults.
Topics: Adolescent; Adult; Age Factors; Area Under Curve; Body Mass Index; Body Weight; Busulfan; Child; Chi | 2012 |
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Topics: Adolescent; Adult; Autoantigens; Bilirubin; Biomarkers; Body Weight; Bone Marrow Transplantation; Bu | 2002 |
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Busulfan; Cyclophosphamide; Dose-Response R | 2003 |
The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.
Topics: Animals; Body Weight; Bone Marrow; Busulfan; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Chime | 2008 |
Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Cell Count; Body Weight; Bone Marrow Cells; Bone M | 2008 |
Mylecytan-sensitive and Mylecytan-resistant strains of inbred SPF mice.
Topics: Animals; Body Weight; Bone Marrow; Bone Marrow Cells; Busulfan; Drug Resistance; Female; Leukocyte C | 1980 |
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Body Weight; Bone Marrow Transplantation; Busulfan; Chil | 1995 |
CD34+ cell immunoselection from G-CSF-alone-primed peripheral blood in children with low body mass.
Topics: Antigens, CD34; Body Weight; Busulfan; Child; Child, Preschool; Granulocyte Colony-Stimulating Facto | 1995 |
Behaviour of spermatogonia following recovery from busulfan treatment in the rat.
Topics: Animals; Body Weight; Busulfan; Cell Division; Cell Polarity; Female; Fertility; Injections, Intrape | 1998 |
The impact of obesity and disease on busulfan oral clearance in adults.
Topics: Administration, Oral; Adolescent; Adult; Body Mass Index; Body Surface Area; Body Weight; Busulfan; | 1999 |
Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Busulfan; Combined Mod | 2000 |
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Area Un | 2001 |
Bone marrow transplantation in the busulfan-treated rat. I. Effect of cyclophosphamide and rabbit antirat thymocyte serum as immunosuppression.
Topics: Animals; Antilymphocyte Serum; Body Weight; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan | 1975 |
[Influence of spermatogenesis on testicular fluid secretion in adult rats].
Topics: Age Factors; Animals; Body Weight; Busulfan; Epididymis; Male; Organ Size; Rats; Seminal Vesicles; S | 1975 |
The endocrine function of rat gonads with reduced number of germ cells following busulphan treatment.
Topics: Aging; Animals; Body Weight; Busulfan; Chorionic Gonadotropin; Estradiol; Female; Fetus; Male; Organ | 1986 |
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Blood Cell Coun | 1985 |
Effects of flutamide or of supplementation with testosterone in prepubertal male rats prenatally treated with busulfan.
Topics: Anilides; Animals; Body Weight; Busulfan; Female; Flutamide; Follicle Stimulating Hormone; Hypothala | 1985 |
The effect of prenatal treatment with busulfan on in vitro androgen production by testes from rats of various ages.
Topics: Aging; Androgens; Animals; Body Weight; Busulfan; Female; Luteinizing Hormone; Male; Maternal-Fetal | 1985 |
Hypothyroidism induced by a transplanted fibrosarcoma in the rat.
Topics: Animals; Body Weight; Busulfan; Cyclophosphamide; Fibrosarcoma; Hypothyroidism; Male; Methylcholanth | 1967 |
Chronic granulomatous disease: quantitative clinicopathological relationships.
Topics: Adolescent; Anemia; Arthritis; Blood Proteins; Body Height; Body Weight; Busulfan; Child; Child, Pre | 1970 |
Observation of dividing spermatocytes for chromosome aberrations induced in mouse spermatogonia by chemical mutagens.
Topics: Alkanesulfonates; Animals; Body Weight; Busulfan; Chromosome Aberrations; Cyclophosphamide; Dose-Res | 1972 |
Pituitary and serum FSH and LH levels after massive and selective depletion of the germinal epithelium in the rat testis.
Topics: Animals; Body Weight; Busulfan; Epithelium; Follicle Stimulating Hormone; Iodine Isotopes; Luteinizi | 1973 |
Testosterone levels in the serum and testes of growing rats following prenatal exposure to busulphan.
Topics: Animals; Body Weight; Busulfan; Female; Injections, Intraperitoneal; Male; Maternal-Fetal Exchange; | 1973 |